CLINICAL_TRIALS
trial_result
· 2020-09-16
Clinical Trial Update: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia [Phase 2]
Summary
Phase 2 trial update on AVP-786 for the treatment of residual schizophrenia reports efficacy, safety, and tolerability findings.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Avanir Pharmaceuticals | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2020-09-16